Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist

Oncotarget

Volumn 7, Issue 23, 2016, Pages 35353-35368

  Grillo, Elisabetta ^a   Ravelli, Cosetta ^a   Corsini, Michela ^a   Ballmer Hofer, Kurt ^b   Zammataro, Luca ^c   Oreste, Pasqua ^d   Zoppetti, Giorgio ^d   Tobia, Chiara ^a   Ronca, Roberto ^a   Presta, Marco ^a   Mitola, Stefania ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^d Glycores2000   (Italy)

Author keywords

Angiogenesis; BMP; Gremlin; Oligomerization; VEGFR2 antagonist

Indexed keywords

ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN; CYSTEINE; GREMLIN; HOMODIMER; MONOMER; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; GREM1 PROTEIN, HUMAN; KDR PROTEIN, HUMAN; SIGNAL PEPTIDE;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; COMPUTER MODEL; CONTROLLED STUDY; COVALENT BOND; DIMERIZATION; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MOUSE; MUTAGENESIS; MUTANT; NONHUMAN; PROSTATE CANCER CELL LINE; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; HETEROGRAFTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84973617077     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9286     Document Type: Article

References (57)

1. Massague J. How cells read TGF-beta signals. Nature reviews Molecular cell biology. 2000; 1:169-178
2. Singh A and Morris RJ. The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine & growth factor reviews. 2010; 21:299-313
3. Dyer LA, Pi X and Patterson C. The role of BMPs in endothelial cell function and dysfunction. Trends in endocrinology and metabolism. 2014
4. Thompson TB, Lerch TF, Cook RW, Woodruff TK and Jardetzky TS. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Developmental cell. 2005; 9:535-543
5. Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W, Affolter M, Vale WW, Izpisua Belmonte JC and Choe S. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature. 2002; 420:636-642
6. Rider CC and Mulloy B. Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. The Biochemical journal. 2010; 429:1-12
7. Khokha MK, Hsu D, Brunet LJ, Dionne MS and Harland RM. Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. Nature genetics. 2003; 34:303-307
8. Lu MM, Yang H, Zhang L, Shu W, Blair DG and Morrisey EE. The bone morphogenic protein antagonist gremlin regulates proximal-distal patterning of the lung. Developmental dynamics. 2001; 222:667-680
9. Michos O, Panman L, Vintersten K, Beier K, Zeller R and Zuniga A. Gremlin-mediated BMP antagonism induces the epithelial-mesenchymal feedback signaling controlling metanephric kidney and limb organogenesis. Development. 2004; 131:3401-3410
10. Murphy M, McMahon R, Lappin DW and Brady HR. Gremlins: is this what renal fibrogenesis has come to? Experimental nephrology. 2002; 10:241-244
11. Namkoong H, Shin SM, Kim HK, Ha SA, Cho GW, Hur SY, Kim TE and Kim JW. The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC cancer. 2006; 6:74
12. Sneddon JB, Zhen HH, Montgomery K, van de Rijn M, Tward AD, West R, Gladstone H, Chang HY, Morganroth GS, Oro AE and Brown PO. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:14842-14847
13. Li Y, Wang Z, Wang S, Zhao J, Zhang J and Huang Y. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes aristolochic acid-induced epithelial-to-mesenchymal transition (EMT) in HK-2 cells. Toxicology. 2012; 297:68-75
14. Stabile H, Mitola S, Moroni E, Belleri M, Nicoli S, Coltrini D, Peri F, Pessi A, Orsatti L, Talamo F, Castronovo V, Waltregny D, Cotelli F, et al. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood. 2007; 109:1834-1840
15. Mitola S, Ravelli C, Moroni E, Salvi V, Leali D, Ballmer-Hofer K, Zammataro L and Presta M. Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood. 2010; 116:3677-3680
16. Corsini M, Moroni E, Ravelli C, Andres G, Grillo E, Ali IH, Brazil DP, Presta M and Mitola S. Cyclic adenosine monophosphate-response element-binding protein mediates the proangiogenic or proinflammatory activity of gremlin. Arteriosclerosis, thrombosis, and vascular biology. 2014; 34:136-145
17. Ravelli C, Grillo E, Corsini M, Coltrini D, Presta M and Mitola S. beta3 Integrin Promotes Long-Lasting Activation and Polarization of Vascular Endothelial Growth Factor Receptor 2 by Immobilized Ligand. Arteriosclerosis, thrombosis, and vascular biology. 2015; 35:2161-2171
18. Chiodelli P, Mitola S, Ravelli C, Oreste P, Rusnati M and Presta M. Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin. Arteriosclerosis, thrombosis, and vascular biology. 2011; 31:e116-127
19. Tatsinkam AJ, Mulloy B and Rider CC. Mapping the heparin-binding site of the BMP antagonist gremlin by sitedirected mutagenesis based on predictive modelling. The Biochemical journal. 2015; 470:53-64
20. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. The Journal of biological chemistry. 2009; 284:10890-10900
21. Avsian-Kretchmer O and Hsueh AJ. Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. Molecular endocrinology. 2004; 18:1-12
22. Kattamuri C, Luedeke DM, Nolan K, Rankin SA, Greis KD, Zorn AM and Thompson TB. Members of the DAN family are BMP antagonists that form highly stable noncovalent dimers. Journal of molecular biology. 2012; 424:313-327
23. Sun J, Zhuang FF, Mullersman JE, Chen H, Robertson EJ, Warburton D, Liu YH and Shi W. BMP4 activation and secretion are negatively regulated by an intracellular gremlin-BMP4 interaction. The Journal of biological chemistry. 2006; 281:29349-29356
24. Topol LZ, Bardot B, Zhang Q, Resau J, Huillard E, Marx M, Calothy G and Blair DG. Biosynthesis, post-translation modification, and functional characterization of Drm/Gremlin. The Journal of biological chemistry. 2000; 275:8785-8793
25. Church RH, Krishnakumar A, Urbanek A, Geschwindner S, Meneely J, Bianchi A, Basta B, Monaghan S, Elliott C, Stromstedt M, Ferguson N, Martin F and Brazil DP. Gremlin1 preferentially binds to Bone Morphogenetic Protein-2 (BMP-2) and BMP-4 over BMP-7. The Biochemical journal. 2015; 466:55-68. doi: 10.1042/BJ20140771
26. Lyskov S and Gray JJ. The RosettaDock server for local protein-protein docking. Nucleic acids research. 2008; 36:W233-238
27. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, Andrews NC and Lin HY. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nature genetics. 2006; 38:531-539
28. Kondo M. Bone morphogenetic proteins in the early development of zebrafish. The FEBS journal. 2007; 274:2960-2967
29. Maiolo D, Mitola S, Leali D, Oliviero G, Ravelli C, Bugatti A, Depero LE, Presta M and Bergese P. Role of nanomechanics in canonical and noncanonical proangiogenic ligand/VEGF receptor-2 activation. Journal of the American Chemical Society. 2012; 134:14573-14579
30. Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G and Aprile G. Clinical advances in the development of novel VEGFR2 inhibitors. Annals of translational medicine. 2014; 2:123
31. Bronte G, Bronte E, Novo G, Pernice G, Lo Vullo F, Musso E, Bronte F, Gulotta E, Rizzo S, Rolfo C, Silvestris N, Bazan V, Novo S, et al. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Expert opinion on drug safety. 2015; 14:253-267
32. Gu JW, Young E, Busby B, Covington J and Johnson JW. Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice. Cancer biology & therapy. 2009; 8:514-521
33. Young E, Miele L, Tucker KB, Huang M, Wells J and Gu JW. SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells. Cancer biology & therapy. 2010; 10:703-711
34. Giacomini A, Matarazzo S, Pagano K, Ragona L, Rezzola S, Corsini M, Di Salle E, Presta M and Ronca R. A long pentraxin-3-derived pentapeptide for the therapy of FGF8bdriven steroid hormone-regulated cancers. Oncotarget. 2015; 6:13790-13802. doi: 10.18632/oncotarget.3831
35. Phani S, Jablonski M, Pelta-Heller J, Cai J and Iacovitti L. Gremlin is a novel VTA derived neuroprotective factor for dopamine neurons. Brain research. 2013; 1500:88-98
36. Lavoz C, Alique M, Rodrigues-Diez R, Pato J, Keri G, Mezzano S, Egido J and Ruiz-Ortega M. Gremlin regulates renal inflammation via vascular endothelial growth factor receptor 2 pathway. The Journal of pathology. 2015; 236:407-20. doi: 10.1002/path.4537
37. Koketsu K, Yoshida D, Kim K, Ishii Y, Tahara S, Teramoto A and Morita A. Gremlin, a bone morphogenetic protein antagonist, is a crucial angiogenic factor in pituitary adenoma. International journal of endocrinology. 2015; 2015:834137
38. Leppanen VM, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, Lankinen H, Goldman A, Ballmer-Hofer K and Alitalo K. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:2425-2430
39. Tolbert WD, Daugherty-Holtrop J, Gherardi E, Vande Woude G and Xu HE. Structural basis for agonism and antagonism of hepatocyte growth factor. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:13264-13269
40. Orlandini M, Marconcini L, Ferruzzi R and Oliviero S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93:11675-11680
41. Toivanen PI, Nieminen T, Viitanen L, Alitalo A, Roschier M, Jauhiainen S, Markkanen JE, Laitinen OH, Airenne TT, Salminen TA, Johnson MS, Airenne KJ and Yla-Herttuala S. Novel vascular endothelial growth factor D variants with increased biological activity. The Journal of biological chemistry. 2009; 284:16037-16048
42. Chiu J, Wong JW, Gerometta M and Hogg PJ. Mechanism of dimerization of a recombinant mature vascular endothelial growth factor C. Biochemistry. 2014; 53:7-9
43. Leppanen VM, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, Toivanen P, Yla-Herttuala S, Ballmer-Hofer K and Alitalo K. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood. 2011; 117:1507-1515
44. Boesen TP, Soni B, Schwartz TW and Halkier T. Singlechain vascular endothelial growth factor variant with antagonist activity. The Journal of biological chemistry. 2002; 277:40335-40341
45. Leenders W, Lubsen N, van Altena M, Clauss M, Deckers M, Lowik C, Breier G, Ruiter D and de Waal R. Design of a variant of vascular endothelial growth factor-A (VEGF-A) antagonizing KDR/Flk-1 and Flt-1. Laboratory investigation; a journal of technical methods and pathology. 2002; 82:473-481
46. Potgens AJ, Lubsen NH, van Altena MC, Vermeulen R, Bakker A, Schoenmakers JG, Ruiter DJ and de Waal RM. Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations. The Journal of biological chemistry. 1994; 269:32879-32885
47. Laurila R, Parkkila S, Isola J, Kallioniemi A and Alarmo EL. The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues. International journal of clinical and experimental pathology. 2013; 6:1400-1408
48. David L, Feige JJ and Bailly S. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine & growth factor reviews. 2009; 20:203-212
49. Grinspan JB, Mueller SN and Levine EM. Bovine endothelial cells transformed in vitro by benzo(a)pyrene. Journal of cellular physiology. 1983; 114:328-338
50. Topol LZ, Marx M, Laugier D, Bogdanova NN, Boubnov NV, Clausen PA, Calothy G and Blair DG. Identification of drm, a novel gene whose expression is suppressed in transformed cells and which can inhibit growth of normal but not transformed cells in culture. Molecular and cellular biology. 1997; 17:4801-4810
51. Thompson JD, Higgins DG and Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic acids research. 1994; 22:4673-4680
52. Chaudhury S, Berrondo M, Weitzner BD, Muthu P, Bergman H and Gray JJ. Benchmarking and analysis of protein docking performance in Rosetta v3.2. PloS one. 2011; 6:e22477
53. Coltrini D, Di Salle E, Ronca R, Belleri M, Testini C and Presta M. Matrigel plug assay: evaluation of the angiogenic response by reverse transcription-quantitative PCR. Angiogenesis. 2013; 16:469-477
54. Ravelli C, Mitola S, Corsini M and Presta M. Involvement of alphavbeta3 integrin in gremlin-induced angiogenesis. Angiogenesis. 2013; 16:235-243
55. Karpova TS, Baumann CT, He L, Wu X, Grammer A, Lipsky P, Hager GL and McNally JG. Fluorescence resonance energy transfer from cyan to yellow fluorescent protein detected by acceptor photobleaching using confocal microscopy and a single laser. Journal of microscopy. 2003; 209:56-70
56. Stepensky D. FRETcalc plugin for calculation of FRET in non-continuous intracellular compartments. Biochemical and biophysical research communications. 2007; 359:752-758
57. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G and Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. The EMBO journal. 1999; 18:882-892